Suppr超能文献

患有不明原因不孕症的女性子宫肌瘤的管理。

The management of uterine fibroids in women with otherwise unexplained infertility.

作者信息

Carranza-Mamane Belina, Havelock Jon, Hemmings Robert

机构信息

Sherbrooke QC.

Vancouver BC.

出版信息

J Obstet Gynaecol Can. 2015 Mar;37(3):277-285. doi: 10.1016/S1701-2163(15)30318-2.

Abstract

OBJECTIVE

To provide recommendations regarding the best management of fibroids in couples who present with infertility. Usual and novel treatment options for fibroids will be reviewed with emphasis on their applicability in women who wish to conceive.

OPTIONS

Management of fibroids in women wishing to conceive first involves documentation of the presence of the fibroid and determination of likelihood of the fibroid impacting on the ability to conceive. Treatment of fibroids in this instance is primarily surgical, but must be weighed against the evidence of surgical management improving clinical outcomes, and risks specific to surgical management and approach.

OUTCOMES

The outcomes of primary concern are the improvement in pregnancy rates and outcomes with management of fibroids in women with infertility.

EVIDENCE

Published literature was retrieved through searches of PubMed, MEDLINE, the Cochrane Library in November 2013 using appropriate controlled vocabulary (e.g., leiomyoma, infertility, uterine artery embolization, fertilization in vitro) and key words (e.g., fibroid, myomectomy). Results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies published in English and French. There were no date restrictions. Searches were updated on a regular basis and incorporated in the guideline to November 2013. Grey (unpublished literature) was identified through searching the websites of health technology assessment and health technology-related agencies, clinical practice guideline collections, clinical trial registries, and national and international medical specialty societies.

VALUES

The quality of evidence in this document was rated using the criteria described by the Canadian Task Force on Preventive Health Care (Table).

BENEFITS, HARMS, AND COSTS: These recommendations are expected to allow adequate management of women with fibroids and infertility, maximizing their chances of pregnancy by minimizing risks introduced by unnecessary myomectomies. Reducing complications and eliminating unnecessary interventions are also expected to decrease costs to the health care system. Summary Statements 1. Subserosal fibroids do not appear to have an impact on fertility; the effect of intramural fibroids remains unclear. If intramural fibroids do have an impact on fertility, it appears to be small and to be even less significant when the endometrium is not involved. (II-3) 2. Because current medical therapy for fibroids is associated with suppression of ovulation, reduction of estrogen production, or disruption of the target action of estrogen or progesterone at the receptor level, and it has the potential to interfere in endometrial development and implantation, there is no role for medical therapy as a stand-alone treatment for fibroids in the infertile population. (III) 3. Preoperative assessment of submucosal fibroids is essential to the decision on the best approach for treatment. (III) 4. There is little evidence on the use of Foley catheters, estrogen, or intrauterine devices for the prevention of intrauterine adhesions following hysteroscopic myomectomy. (II-3) 5. In the infertile population, cumulative pregnancy rates by the laparoscopic and the minilaparotomy approaches are similar, but the laparoscopic approach is associated with a quicker recovery, less postoperative pain, and less febrile morbidity. (II-2) 6. There are lower pregnancy rates, higher miscarriage rates, and more adverse pregnancy outcomes following uterine artery embolization than after myomectomy. (II-3) Studies also suggest that uterine artery embolization is associated with loss of ovarian reserve, especially in older patients. (III) Recommendations 1. In women with infertility, an effort should be made to adequately evaluate and classify fibroids, particularly those impinging on the endometrial cavity, using transvaginal ultrasound, hysteroscopy, hysterosonography, or magnetic resonance imaging. (III-A) 2. Preoperative assessment of submucosal fibroids should include, in addition to an assessment of fibroid size and location within the uterine cavity, evaluation of the degree of invasion of the cavity and thickness of residual myometrium to the serosa. A combination of hysteroscopy and transvaginal ultrasound or hysterosonography are the modalities of choice. (III-B) 3. Submucosal fibroids are managed hysteroscopically. The fibroid size should be < 5 cm, although larger fibroids have been managed hysteroscopically, but repeat procedures are often necessary. (III-B) 4. A hysterosalpingogram is not an appropriate exam to evaluate and classify fibroids. (III-D)  5. In women with otherwise unexplained infertility, submucosal fibroids should be removed in order to improve conception and pregnancy rates. (II-2A) 6. Removal of subserosal fibroids is not recommended. (III-D) 7. There is fair evidence to recommend against myomectomy in women with intramural fibroids (hysteroscopically confirmed intact endometrium) and otherwise unexplained infertility, regardless of their size. (II-2D) If the patient has no other options, the benefits of myomectomy should be weighed against the risks, and management of intramural fibroids should be individualized. (III-C) 8. If fibroids are removed abdominally, efforts should be made to use an anterior uterine incision to minimize the formation of postoperative adhesions. (II-2A) 9. Widespread use of the laparoscopic approach to myomectomy may be limited by the technical difficulty of this procedure. Patient selection should be individualized based on the number, size, and location of uterine fibroids and the skill of the surgeon. (III-A) 10. Women, fertile or infertile, seeking future pregnancy should not generally be offered uterine artery embolization as a treatment option for uterine fibroids. (II-3E).

摘要

目的

为患有不孕症的夫妇中子宫肌瘤的最佳管理提供建议。将对子宫肌瘤的常规和新型治疗选择进行综述,重点关注其在希望受孕的女性中的适用性。

选择

希望受孕的女性中子宫肌瘤的管理首先涉及记录子宫肌瘤的存在情况,并确定子宫肌瘤影响受孕能力的可能性。在这种情况下,子宫肌瘤的治疗主要是手术治疗,但必须权衡手术管理改善临床结局的证据,以及手术管理和方法所特有的风险。

结果

主要关注的结果是不孕症女性中子宫肌瘤管理后妊娠率和结局的改善。

证据

通过2013年11月检索PubMed、MEDLINE、Cochrane图书馆,使用适当的控制词汇(如平滑肌瘤、不孕症、子宫动脉栓塞、体外受精)和关键词(如子宫肌瘤、肌瘤切除术)检索已发表的文献。结果仅限于系统评价、随机对照试验/对照临床试验以及以英文和法文发表的观察性研究。没有日期限制。检索定期更新,并纳入截至2013年11月的指南。通过搜索卫生技术评估和卫生技术相关机构的网站、临床实践指南汇编、临床试验注册库以及国家和国际医学专业协会来识别灰色文献(未发表的文献)。

价值

本文件中的证据质量使用加拿大预防性医疗保健工作组描述的标准进行评级(表)。

益处、危害和成本:这些建议预计将使患有子宫肌瘤和不孕症的女性得到充分管理,通过将不必要的肌瘤切除术引入的风险降至最低,最大限度地提高她们的受孕机会。减少并发症和消除不必要的干预措施预计也将降低医疗保健系统的成本。

总结声明

1.浆膜下子宫肌瘤似乎对生育能力没有影响;肌壁间子宫肌瘤的影响尚不清楚。如果肌壁间子宫肌瘤确实对生育能力有影响,其影响似乎较小,并且当子宫内膜未受累时影响更小。(II-3)

2.由于目前子宫肌瘤的药物治疗与抑制排卵、减少雌激素产生或在受体水平干扰雌激素或孕激素的靶作用有关,并且它有可能干扰子宫内膜发育和着床,因此药物治疗在不育人群中不作为子宫肌瘤的单一治疗方法。(III)

3.黏膜下子宫肌瘤的术前评估对于决定最佳治疗方法至关重要。(III)

4.关于使用 Foley 导管、雌激素或宫内节育器预防宫腔镜子宫肌瘤切除术后宫腔粘连的证据很少。(II-3)

5.在不育人群中,腹腔镜和小切口剖腹手术方法的累积妊娠率相似,但腹腔镜方法恢复更快、术后疼痛更少且发热发病率更低。(II-2)

6.子宫动脉栓塞术后的妊娠率低于肌瘤切除术后,流产率更高,不良妊娠结局更多。(II-3)研究还表明,子宫动脉栓塞与卵巢储备丧失有关,尤其是在老年患者中。(III)

建议

1.对于患有不孕症的女性,应努力使用经阴道超声、宫腔镜检查、子宫超声造影或磁共振成像对子宫肌瘤进行充分评估和分类,特别是那些侵犯子宫内膜腔的肌瘤。(III-A)

2.黏膜下子宫肌瘤的术前评估除了评估肌瘤大小和在子宫腔内的位置外,还应包括评估肌瘤侵犯宫腔的程度以及残余肌层至浆膜的厚度。宫腔镜检查与经阴道超声或子宫超声造影相结合是首选的检查方法。(III-B)

3.黏膜下子宫肌瘤采用宫腔镜治疗。肌瘤大小应<5 cm,尽管较大的肌瘤也可采用宫腔镜治疗,但通常需要重复手术。(III-B)

4.子宫输卵管造影不是评估和分类子宫肌瘤的合适检查。(III-D)

5.对于其他方面原因不明的不孕症女性,应切除黏膜下子宫肌瘤以提高受孕率和妊娠率。(II-2A)

6.不建议切除浆膜下子宫肌瘤。(III-D)

7.有充分证据反对对肌壁间子宫肌瘤(宫腔镜证实子宫内膜完整)且其他方面原因不明的不孕症女性进行肌瘤切除术,无论其大小如何。(II-2D)如果患者没有其他选择,应权衡肌瘤切除术的益处和风险,肌壁间子宫肌瘤的管理应个体化。(III-C)

8.如果经腹部切除子宫肌瘤,应尽量采用子宫前壁切口以减少术后粘连的形成。(II-2A)

9.腹腔镜肌瘤切除术的广泛应用可能受到该手术技术难度的限制。应根据子宫肌瘤的数量、大小和位置以及外科医生的技术水平对患者进行个体化选择。(III-A)

1". 一般而言,寻求未来妊娠的有生育能力或不育的女性不应将子宫动脉栓塞作为子宫肌瘤的治疗选择。(II-3E)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验